|
Patent landscape, scope, and claims: |
US Patent 10,034,879 Scope, Claims, and Patent Landscape Analysis (US Drug Patent)
US Patent 10,034,879 is directed to (i) a specific chemical compound defined by a structural formula and (ii) a solid oral dosage form containing that compound with pharmaceutically acceptable excipients. The claim set as provided indicates a typical “compound + formulation” structure with enforceable coverage over the defined active entity and over solid dosage forms that incorporate it.
This analysis maps claim scope at the structural level, identifies typical infringement/invalidity pressure points for this claim type, and outlines how this patent usually fits into a broader US patent estate around a candidate drug product (compound, polymorph/salt, formulation, method-of-use, and process patents).
What does US Patent 10,034,879 claim: compound structure vs solid dosage form?
Short answer: The patent claims cover (1) the compound itself (by chemical structure) and (2) solid dosage forms comprising that compound plus pharmaceutically acceptable excipients.
Claim 1 scope: “A compound having the structure”
Claim 1 is a Markush-style “compound of structure X” claim in practice, even if not explicitly called Markush. Coverage turns on whether an accused compound contains the full structural features recited in the claim’s formula.
Scope drivers
- Exact core scaffold: The claim’s structure defines the backbone and substitution pattern. If any required ring, linker, stereochemical element, or substituent is missing or replaced, non-infringement risk increases.
- Stereochemistry and isomerism: If the claim structure encodes stereocenters or defines relative/absolute configuration through wedge/dash or hashed bonds, stereochemical substitutions can narrow infringement.
- Defined substituents: If the claim formula includes variable substituents defined by ranges, those ranges control breadth. If the provided structure is fully specified, breadth is narrower.
Typical legal posture for this claim type
- Infringement: Usually assessed by chemical structure comparison plus, in litigation, analytical confirmation (NMR, LC-MS, chiral HPLC, crystallography).
- Enablement/clarity: Depends on how fully the patent teaches synthesis and characterization for the specific claimed structure, and whether the claim is sufficiently definite to permit one skilled in the art to make and use the claimed compound without undue experimentation.
- Novelty/obviousness: The core debate is whether the structure (or close analogs) was disclosed in the prior art, and whether the claimed substitution pattern would have been obvious.
Claim 2 scope: “A solid dosage form comprising … and a pharmaceutically acceptable excipient”
Claim 2 covers a dosage form that includes the claimed compound and excipients and is limited to solid dosage forms.
Scope drivers
- “Solid dosage form”: Typically includes tablets, capsules, granules, and powders intended for oral administration. It usually excludes true liquid formulations unless “solidified” forms are implicated.
- “Comprising”: The language “comprising” normally permits additional ingredients beyond the compound and excipients while keeping the claim satisfied as long as the claimed compound is present.
- Excipient definition: “Pharmaceutically acceptable excipient” is broad and usually not limiting unless the claim specifies functional or quantitative excipient characteristics (the provided claim text does not).
Key narrowing factors
- If the patent specification restricts the formulation (particle size, binder types, coatings, disintegration profile, or specific salt/polymorph forms), the prosecution record and written description can be used to argue claim scope limits. On the other hand, if the claim does not recite those features, challengers face a tighter path to narrow the claim through “implicit limitations.”
How broad is a “compound structure” claim in US litigation?
Short answer: Breadth is defined by the precision of the structural formula and any stereochemical or substituent constraints encoded in the claim drawing or text.
Structure-only claims: what typically decides claim breadth
- Exactness of the formula
- A single omitted functional group, different linker length, or alternative heteroatom can avoid literal infringement.
- Stereochemical requirement
- If the claim is configured to a specific stereoisomer, an alternative stereoisomer can be designed around.
- Salt/polymorph reality check
- If the patent claims “a compound” without expressly covering salts or solvates, defendants often argue that a salt is not the “compound” as defined. Courts then look to claim language and definition in the specification.
Equivalents
Even if literal infringement is avoided by a small chemical modification, equivalence arguments depend on:
- interchangeability of the structure feature,
- whether the difference was known to be interchangeable,
- and whether a prosecution history estoppel exists for that feature.
Your provided excerpt does not include prosecution history or full claim set, so this stays at the general level for this claim architecture.
What patent landscape usually surrounds a US compound + solid dosage claim?
Short answer: Drug estates with compound claims plus solid oral dosage claims commonly include parallel patent families covering salt/polymorphs, particle engineering, scalable synthesis, specific manufacturing process, and method-of-use.
Common US patent types in the same estate
- Salt and polymorph claims
Cover crystalline forms, amorphous forms, and salts/hydrates of the same active entity.
- Formulation details
Tablets and capsules may be claimed again with excipient compositions, coating systems, disintegrants, binders, and dissolution targets.
- Manufacturing/process patents
Solid-state processing, milling conditions, crystallization conditions, and drying parameters.
- Method-of-use claims
Indications, dosing regimens, and patient subsets.
- Combination patents
The compound paired with another therapeutic agent in specific regimens.
How to interpret risk from only Claim 1 and Claim 2
- If only compound and generic “solid dosage form” claims exist, competitors can sometimes mitigate risk via:
- alternative stereoisomer (if allowable),
- alternative salt form (if the claim does not cover salts),
- amorphous conversion (if the compound’s defined form is constrained elsewhere),
- or formulation workarounds that avoid “solid dosage form” (often unrealistic for oral generics).
- If additional claims exist in the full patent not shown in your excerpt, risk typically increases due to polymorph, salt, and process coverage.
What makes a solid dosage form claim vulnerable: prior art formulations vs chemistry
Short answer: Claim 2’s breadth (“solid dosage form comprising compound + excipient”) is often challenged for obviousness over prior art tablets, capsules, or solid oral formulations using closely related compounds.
Obviousness pathways typically used against formulation-only coverage
- Prior art shows that formulating the claimed compound (or close analogs) into a solid oral form was routine.
- Prior art discloses excipient selection and general manufacturing methods for similar actives.
- If claim 2 lacks functional limitations (e.g., dissolution profile, bioavailability window), obviousness arguments can be easier.
Defenses that strengthen formulation claims
- Specification supports unexpected properties:
- improved bioavailability,
- controlled release behavior,
- reduced variability,
- stability advantages.
- Dependent claims (not provided) often supply these limitations. With only a high-level “solid dosage form” claim, the strength is typically lower than a formulation claim that recites specific excipient ranges or performance.
Where do generics enter relative to patents like 10,034,879?
Short answer: For US small molecules, generics often file ANDAs and must navigate Orange Book-listed patents. Compound and formulation patents can delay approval depending on which patents are listed for the specific NDA product and the relevant expiration timelines.
Key decision point: Orange Book listing
Enforcement and launch blocking depend on whether US Patent 10,034,879 is listed in the FDA Orange Book for a specific drug product tied to this patent’s compound.
In practice, the landscape analysis must be driven by:
- the Orange Book drug product mapping,
- patent expiration date,
- whether an ANDA filer faces a paragraph IV challenge,
- settlement terms.
Your provided excerpt does not include the Orange Book mapping, expiration date, listed NDA/BLA application, or litigation record.
What is the likely remaining exclusivity profile for US Patent 10,034,879?
Short answer: The remaining term depends on (i) filing date, (ii) patent term adjustment (PTA), (iii) terminal disclaimer structure, and (iv) whether pediatric extension applies. Without bibliographic data (filing date, assignee, PTA), a timeline cannot be computed from the claim excerpt alone.
How can competitors design around compound structure claims like Claim 1?
Short answer: Most design-around strategies for structure claims target missing required atoms/groups, stereochemical changes, or different salt/form.
Design-around levers that typically succeed
- Change a required substituent to a different group not within what the structure requires (if the structure is fully specified).
- Use the alternate enantiomer or diastereomer if stereochemistry is part of the claim.
- Convert to a salt or solvate if claim language or definitions exclude those forms.
- Use a different crystal form if the patent’s “compound” definition is tied to a particular solid-state form (this depends on full claim set and spec support).
Design-around levers that usually fail
- Small modifications that still reproduce the claimed structure (equivalence risk).
- “Avoiding dosage form” by switching to another dosage route when the competitor’s product is still oral solid (claim 2 may still be read broadly).
What patent strength indicators matter for a compound + tablet excipient claim?
Short answer: Strength is highest when:
- the claim is narrow enough to map to the specific disclosed molecule and form,
- the specification provides robust support for the structure,
- and the patent family covers multiple orthogonal patent angles (salt/polymorph, process, method-of-use).
Strength is weaker when:
- the claim is purely structural with broad definition and relies on generic oral formulation capability without performance limitations,
- or when the family lacks additional dependent claims to create coverage redundancy.
Your excerpt provides only the high-level claim text.
What litigation and licensing scenarios typically involve this kind of patent?
Short answer: Structure and formulation patents are frequent targets in US generic litigation because they can block approval even if the generic develops a different process, and they can be used to negotiate settlements.
Common patterns:
- Paragraph IV challenges by ANDA filers against compound and formulation patents.
- Settlement agreements that delay generic launch until the relevant patent expiration.
- License agreements that permit earlier entry at reduced or royalties.
A litigation landscape requires the docket-level record and Orange Book data.
Which jurisdictions and claim coverage are most relevant beyond the US?
Short answer: For a US patent like 10,034,879, enforcement and competitive risk often track the same patent family’s presence in key markets:
- EP (EPO) and UK,
- CN,
- JP,
- KR,
- IN.
But the geographic scope depends on whether this patent belongs to a PCT family with filings and how those were amended. No family members were provided in the prompt.
Patent landscape table: What this patent likely covers inside the drug estate
Because only Claim 1 and Claim 2 text were provided, the table below maps typical estate elements rather than enumerating specific family patents.
| Estate layer |
Typical claim scope |
How it affects generic entry |
| Compound (US Patent like 10,034,879 Claim 1) |
Specific chemical structure |
Blocks approval if ANDA product uses the same active (or a covered form) |
| Solid formulation (Claim 2) |
Oral solid with compound + excipients |
Blocks approval even if process differs; may be easier to challenge on obviousness if generic prior art exists |
| Salt/polymorph |
Same active in different solid-state |
Generic may try alternative salt/polymorph to avoid “compound” or formulation read-through |
| Process |
Synthesis/crystallization steps |
Often used as secondary leverage; can be hard for generic to design around if process is embedded |
| Method-of-use |
Indication/dose regimen |
Can block approval if generic attempts to market for protected indications |
| Combination |
Compound + second agent |
Blocks branded combo and may affect switching strategies |
Key Takeaways
- US Patent 10,034,879 (as characterized by the provided claims) covers two enforceable buckets: the specific chemical compound by structure (Claim 1) and an oral solid dosage form comprising that compound and pharmaceutically acceptable excipients (Claim 2).
- Claim 1 risk is highest for entrants using the same stereochemical and substituent-defined molecule. Claim 2 risk is highest when the generic product is an oral solid formulation containing the claimed active plus standard excipients.
- The real-world exclusivity and generic launch risk depends on Orange Book listing, patent expiration mechanics (filing date, PTA, extensions), and whether challengers mounted paragraph IV actions with settlements. Those facts are not in the prompt, so they cannot be stated.
FAQs
-
Does a “compound by structure” claim cover salts and solvates?
Depends on claim definitions and specification; “a compound” can be interpreted broadly or narrowly depending on how the patent defines salt/solvate coverage.
-
Can an ANDA avoid infringement by changing the excipient composition?
For a “comprising compound and pharmaceutically acceptable excipient” claim, changing excipients may not avoid infringement if the formulation still contains the claimed compound and uses excipients that remain “pharmaceutically acceptable.”
-
What is the most common design-around for structure claims with stereochemistry?
Switching to a non-covered stereoisomer or modifying stereochemical features that are explicitly recited in the claimed structure.
-
Are solid oral dosage formulation claims easier to invalidate than compound claims?
Often yes if the claim is broad and performance limitations are absent, because routine formulation prior art can support obviousness.
-
How does settlement affect the practical patent landscape for compound + formulation patents?
Settlements can delay generic launch regardless of the ultimate merits, and they can also define design-around requirements or non-marketing commitments that persist through the settlement term.
References (APA)
- USPTO. “United States Patent No. 10,034,879.” United States Patent and Trademark Office (USPTO). (No bibliographic details provided in prompt).
More… ↓
⤷ Start Trial
|
